Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes

Journal of International Medical Research

Volumn 39, Issue 4, 2011, Pages 1504-1512

  Tanaka, M ^a  

^a TENRI HOSPITAL   (Japan)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme a reductase inhibitors; Atorvastatin; Glycaemic control; Hypercholesterolaemia; Renal function; Statins; Type 2 diabetes

Indexed keywords

ATORVASTATIN; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80052232669     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900440     Document Type: Article

References (36)

1. Haffner SM, Lehto S, Ronnemaa T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
2. Stamler J, Vaccaro O, Neaton JD, et al: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-444.
3. Wannamethee G, Whincup PH, Shaper AG, et al: Factors determining case fatality in myocardial infarction "who dies in a heart attack"? Br Heart J 1995; 74: 324-331.
4. Ho JE, Paultre F, Mosca L: Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project. Stroke 2003; 34: 2812-2816.
5. de Jong G, van Raak L, Kessels F, et al: Stroke subtype and mortality: a follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 2003; 56: 262-268.
6. Nakamura H, Arakawa K, Itakura H, et al: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study). Lancet 2006; 368: 1155-1163.
7. Shepherd J, Barter P, Carmena R, et al: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-1226.
8. Sever PS, Poulter NR, Dahlof B, et al: Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005; 28: 1151-1157.
9. Athyros VG, Papageorgiou AA, Mercouris BR, et al: Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-228.
10. Colhoun HM, Betteridge DJ, Duttington PN, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebocontrolled trial. Lancet 2004; 364: 685-696.
11. Delahoy PJ, Magliano DJ, Webb K, et al: The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 2009; 31: 236-244.
12. Douglas K, O'Malley PG, Jackson JL: Metaanalysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-124.
13. Shepherd J, Kastelein JJP, Bittner V, et al: Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol 2007; 2: 131-1139.
14. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-734.
15. Colhoun HM, Betteridge DJ, Durrington PN, et al: Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the collaborative atorvastatin diabetes study (CARDS). Am J Kidney Dis 2009; 54: 810-819.
16. Vidt DG, Cressman MD, Harris S, et al: Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102: 52-60.
17. Kjekshus J, Apetrei E, Barrios V, et al: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
18. Sever PS, Dahlof B, Poulter NR, et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-1158.
19. Keech A, Colquhoun D, Best J, et al: Secondary prevention of cardiovascular events with longterm pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713-2721.
20. Freeman DJ, Norrie J, Sattar N, et al: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.
21. Collins R, Armitage J, Parish S, et al. for the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
22. Ridker PM, Danielson E, Fonseca FA, et al: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
23. Turner RC, Millns H, Neil HA, et al: Risk factor for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316: 823-828.
24. Rajpathak SN, Kumbhani DJ, Crandall J, et al: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32: 1924-1929.
25. Sattar N, Preiss D, Murray HM, et al: Statins and risk of incident diabetes: a collaborative metaanalysis of randomized statin trials. Lancet 2010; 375: 735-742.
26. Stalenhoef AF, Ballantyne CM, Sarti C, et al: A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005; 26: 2664-2672.
27. Yudkin JS, Richter B: Intensive glucose control and cardiovascular outcomes. Lancet 2009; 374: 522.
28. Keith DS, Nichols GA, Gullion CM, et al: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663.
29. Kottgen A, Russell SD, Loehr LR, et al: Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2007; 18: 1307-1315.
30. Irie F, Iso H, Sairenchi T, et al: The relationship of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69: 1264-1271.
31. Gerstein HC, Mann JF, Yi Q, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
32. Hillege HL, Fidler V, Diercks GF, et al: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
33. Asselbergs FW, Diercks GF, Hillege HL, et al: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-2816.
34. de Zeeuw D, Remuzzi G, Parving HH, et al: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
35. Olsen MH, Wachtell K, Ibsen H, et al: Reduction in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24: 775-781.
36. Sandhu S, Wiebe N, Fried LF, et al: Statins for improving renal outcomes: meta-analysis. J Am Soc Nephrol 2006; 17: 2006-2016.